A number of firms have modified their ratings and price targets on shares of Progenics Pharmaceuticals (NASDAQ: PGNX) recently:
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) opened at 8.49 on Friday. The stock has a market capitalization of $594.73 million, a price-to-earnings ratio of 54.77 and a beta of 2.77. The stock’s 50 day moving average is $6.35 and its 200 day moving average is $5.78. Progenics Pharmaceuticals, Inc. has a one year low of $3.61 and a one year high of $8.50.